MedPath

Artery Embolization vs Operation of Benign Prostate Hyperplasia

Not Applicable
Recruiting
Conditions
Post-Op Complication
Benign Prostatic Hyperplasia
Embolization Therapeutic
Transurethral Resection of Prostate Syndrome
Registration Number
NCT04084938
Lead Sponsor
Oslo University Hospital
Brief Summary

Aim of the study is to compare prostate artery embolization (PAE) to the established surgical treatment for patient acceptance, morbidity, complications, and the functional outcomes. To compare length of stay, hospital costs and time for recovery. 140 patients will be randomized to PAE or surgery. Patients should suffer from lower urinary tract symptoms (LUTS), be candidates for both treatments and willing to undergo both procedures. Before randomization computed tomography angiography of the pelvic arteries is done to select eligible patients. Magnetic resonance imaging of prostate rules out possible cancer. The PAE is done in the angio suite in the radiology department injecting small particles into the prostate arteries. The surgery is done in the operation room in the urology department according to established procedures. Clinical follow-up include clinical visit after 3 months, 1 and 5 years. Acute as well as long term complications will be recorded.

Detailed Description

Background: Prostatic artery embolization (PAE) has recently been described as a promising alternative to surgery for treatment of lower urinary tract symptoms (LUTS) due to an enlarged, benign prostate. The treatment has not been implemented into international guidelines and has only been introduced to few patients in Norway.

Purpose: To compare PAE to the established surgical treatment for patient acceptance, morbidity, complications, and the functional outcomes. To compare length of stay, hospital costs and time for recovery.

Materials and Methods: 140 patients will be randomized to PAE or surgery. Patients should suffer from LUTS, be candidates for both treatments and willing to undergo both procedures. Before randomization computed tomography angiography of the pelvic arteries is done to select eligible patients. Magnetic resonance imaging of prostate rules out possible cancer. The PAE is done in the angio suite in the radiology department injection small particles into the prostate arteries. The surgery is done in the operation room in the urology department according to established procedures. All patients stay in the urology unit after the procedure. Clinical follow-up include clinical visit after 3 months, 1 and 5 years. Acute as well as long term complications will be recorded. The patients fill in the form of quality of life from urologic disease. Urodynamic examination will record functional outcome. Length of stay, procedure costs and recovery time will be recorded.

Importance of the study: Contribute to establishment of new treatment and help to select the right patients for the alternative treatments. Randomized study will give important information to the international community. It is possible to run this study in Norway because it is still in limited use.

Recruitment & Eligibility

Status
RECRUITING
Sex
Male
Target Recruitment
140
Inclusion Criteria
  • LUTS from Benign Prostate Hyperplasia (BPH) with moderate and severe IPSS score (IPSS > 8) and QoL = or >3
  • and refractory to medical treatment for at least 6 months or the patient is unwilling to accept medical treatment
  • or BPH using permanent or intermittent catheterization
  • Prostate volume > 50 ml
  • Signed informed consent
Exclusion Criteria
  • Urological disorders: evidence of clinically significant prostate cancer [as defined by START criteria] on prostate biopsy (27,28), prostatitis (29,30), detrusor-sphincter dyssynergia or evidence of neurogenic bladder, urethral strictures, bladder neck contracture, bladder stone or bladder cancer
  • Renal insufficiency defined as Glomerular Filtration Rate < 30 ml/min/1,73m2
  • Known severe reactions to iodine-based contrast or gadolinium-based contrast
  • Previous prostate operation
  • CT examination reveals no access to the prostate arteries.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Quality of life due to urinary symptoms3 months

"Quality of life due to urinary symptoms" QoL = or \<3 The scale used: Quality of Life Due to Urinary Symptoms. Scale from 0 to 6, the worse is 6. The patient question: If you were to spend the rest of Your life With Your urinary condition just the way it is now, how would you feel about that?

Number of patients with Prostate Artery Embolization that did not have prostate operation12 months

The investigators will record the number of patients that did not have prostate surgery after Prostate Artery Embolization. After 3 months the patients will be offered operation when Quality of Life Due to Urinary Symptoms is 4-6 on the scale from 0-6 ie. the patients report unsatisfied (4), unhappy (5) or terrible (6).

Secondary Outcome Measures
NameTimeMethod
Number of patients with postoperative complications3 months

Postoperative complications will be recorded according to the Clavien-Dindo classification system. Complication will be recorded during hospital stay, at the follow-up after 3 months and at any intermediate points reported by the patients

Hospital stay3 months

Length of stay including before and after the intervention

Symptoms3 months, 1 year, 5 years

Change in IPSS. The patients fill in the form International Prostate Symptom Score (IPSS) before and after treatment. Seven questions are scored from 0 to 5, 5 is the worst outcome. Total score from 0 - 35. 1-7 is mild symptoms, 8-19 is moderate symptoms, 20-35 is severe symptoms.

Trial Locations

Locations (1)

Oslo University Hospital, Aker

🇳🇴

Oslo, Norway

Oslo University Hospital, Aker
🇳🇴Oslo, Norway
Thijs Hagen, MD
Contact
+4745002349
thihag@ous-hf.no
Eduard Baco, MD, PHD
Contact
+4795221378
eduaba@online.no
Nils Einar Kløw, MD, PHD
Principal Investigator
Ole Jørgen Grøtta, MD, PHD
Sub Investigator
Erik Rud, MD, PHD
Sub Investigator
Gunnar Sandbæk, MD, PHD
Sub Investigator
Dag Bay, MD
Sub Investigator
Truls E Bjerklund Johansen, MD, PHD
Sub Investigator
Rolf Eigil Berg, MD, PHD
Sub Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.